We found that the existence of CD68+ cells in TLSs was an independent prognostic factor in recurrent breast cancer, and PFS was significantly improved in patients with CD68+ cells in TLSs than in those without (HR: 0.411, 95% CI: 0.180–0.940, p = 0.035; Table S3). The gene discussed is CD68; the disease is breast cancer.